Unity Biotechnology Inc (NASDAQ:UBX) has earned a consensus broker rating score of 1.17 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. One investment analyst has rated the stock with a buy recommendation and two have issued a strong buy recommendation on the company. Unity Biotechnology’s rating score has improved by 6.4% from three months ago as a result of various analysts’ ratings changes.
Analysts have set a 1-year consensus price objective of $28.50 for the company and are anticipating that the company will post ($0.30) EPS for the current quarter, according to Zacks. Zacks has also assigned Unity Biotechnology an industry rank of 82 out of 255 based on the ratings given to related companies.
A number of brokerages recently weighed in on UBX. Mizuho began coverage on shares of Unity Biotechnology in a report on Thursday, September 6th. They issued a “buy” rating and a $33.00 price target on the stock. Zacks Investment Research raised shares of Unity Biotechnology from a “hold” rating to a “buy” rating and set a $18.00 price target on the stock in a report on Wednesday, August 15th.
A number of institutional investors have recently made changes to their positions in UBX. Baillie Gifford & Co. bought a new stake in Unity Biotechnology in the 2nd quarter valued at about $57,274,000. Gilder Gagnon Howe & Co. LLC bought a new stake in Unity Biotechnology in the 2nd quarter valued at about $301,000. Dean Capital Investments Management LLC bought a new stake in Unity Biotechnology in the 2nd quarter valued at about $543,000. Bank of New York Mellon Corp bought a new stake in Unity Biotechnology in the 2nd quarter valued at about $168,000. Finally, NF Trinity Capital Hong Kong Ltd bought a new stake in Unity Biotechnology in the 2nd quarter valued at about $9,157,000. Institutional investors and hedge funds own 30.25% of the company’s stock.
Shares of NASDAQ:UBX traded down $0.43 during midday trading on Thursday, reaching $11.30. The company had a trading volume of 149,257 shares, compared to its average volume of 160,833. Unity Biotechnology has a 52-week low of $11.12 and a 52-week high of $24.56.
Unity Biotechnology (NASDAQ:UBX) last issued its quarterly earnings results on Thursday, August 9th. The company reported ($0.69) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.31) by ($0.38). On average, analysts expect that Unity Biotechnology will post -1.19 EPS for the current year.
Unity Biotechnology Company Profile
Unity Biotechnology, Inc, a preclinical biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 for musculoskeletal disease with an initial focus on osteoarthritis; and UBX1967 for ophthalmologic diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.